IRCT20200722048176N1 IRCT 2020-08-03 Arak University of Medical Sciences Comparison the Effect of Empaglifluzin and Linagliptin on the Albuminuria of diabetic patients Comparison of the Effect of Empaglifluzin and Linagliptin on the Albuminuria of patients with diabetes mellitus type 2 patients 2020-09-01 anticipated 60 Complete https://irct.ir/trial/49846 interventional Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Randomization method of this study is performed according to the random allocation rule, by first preparing a uniform and sealed envelope based on the total samples and an equal number of samples of each group, inside the envelopes on which the number one are written for the first intervention group and the number two are written for the second intervention group and patients randomly pick up an envelope when entering the study and allocate based on the numbers in the envelopes, Blinding description: In this study, both the patient and the person entering the information into the checklist do not know what group the patient is in. The study is a double-blind study. Participants are blinded by identifying the shape of the drugs and similar packaging. To blind the data collector, the checklist header is removed so that it is not clear to which group the patient belongs. 3 Diabetic Nephropathy. Intervention 1: For patients in the first intervention group, 10 mg of Empagliflozin (manufactured by Dr. Abidi Pharmaceutical Company under the brand name Gloripa) is administered orally once daily for ninety days or three months. Intervention 2: For patients in the second intervention group, Linagliptin 5 mg (manufactured by Dr. Abidi Pharmaceutical Company under the brand name Lirenta) is administered orally once daily for ninety days or three months. Undecided - It is not yet known if there will be a plan to make this available Justification or reason for indecision in sharing IPD is There is no more information.